KLRS
Kalaris Therapeutics

98
Mkt Cap
$155.79M
Volume
187,241.00
52W High
$12.90
52W Low
$2.14
PE Ratio
-1.20
KLRS Fundamentals
Price
$8.87
Prev Close
$8.33
Open
$8.45
50D MA
$5.69
Beta
1.06
Avg. Volume
158,928.00
EPS (Annual)
-$11.73
P/B
3.96
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Monday Sector Laggards: Biotechnology, Electronic Equipment & Products
In trading on Monday, biotechnology shares were relative laggards, down on the day by about 3%. Helping drag down the group were shares of Quince Therapeutics, down about 16.2% and shares of Kalaris...
Nasdaq News: Markets·12d ago
News Placeholder
More News
News Placeholder
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the five research firms that are covering the company, Marketbeat.com...
MarketBeat·14d ago
News Placeholder
Leerink Partnrs Issues Pessimistic Outlook for KLRS Earnings
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) - Research analysts at Leerink Partnrs dropped their Q4 2025 EPS estimates for Kalaris Therapeutics in a report issued on Monday, November 17th...
MarketBeat·22d ago
News Placeholder
What is William Blair's Estimate for KLRS FY2025 Earnings?
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Free Report) - Research analysts at William Blair decreased their FY2025 earnings per share estimates for shares of Kalaris Therapeutics in a research note...
MarketBeat·28d ago
News Placeholder
Kalaris Therapeutics (NASDAQ:KLRS) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.64) EPS for the quarter, beating analysts' consensus estimates of...
MarketBeat·29d ago
News Placeholder
Kalaris Therapeutics Inc. (KLRS) Upgraded to Buy: Here's What You Should Know
Kalaris Therapeutics Inc. (KLRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·3mo ago

Latest KLRS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.